Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
507.00    2.00 (0.40%)
Bid:
506.50
Ask:
508.00
Spread: 1.50 (0.296%)
Market Cap: £2.24b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Trading Statement

8 Oct 2015 07:00

8 October 2015 - Tate & Lyle PLC

Trading Update

Tate & Lyle issues the following trading update for the six months ended 30 September 2015 ahead of the announcement of Half Year Results on Thursday 5 November 2015.

OPERATING PERFORMANCE – CONTINUING OPERATIONS

The Group’s trading performance in the first half was in line with our expectations and guidance for the full year remains unchanged.

Speciality Food Ingredients performed encouragingly and ahead of the comparative period. As anticipated, the Speciality Food Ingredients business returned to volume growth in the second quarter. Volumes were also ahead of the comparative period in SPLENDA® Sucralose and, following the Gemacom acquisition, strongly ahead in Food Systems.

Bulk Ingredients, excluding commodities (ethanol and co-products), continued to perform steadily and slightly ahead of the comparative period supported by solid sweetener demand. Commodities, which continued to be impacted by low US ethanol margins, were significantly lower than the comparative period, and, as a result, Bulk Ingredients overall performed below the comparative period.

The annual bulk sweetener pricing round is in progress. As previously communicated, toll contracts represent around 75% of our US corn sweetener volumes, significantly reducing the volume of our business that is re-contracted in any single year.

EASTSTARCH RE-ALIGNMENT

The process of obtaining regulatory approval for the re-alignment of the Eaststarch joint venture in Europe is now concluded and we expect to complete this transaction during the third quarter of the financial year.

The Group will report the results of the disposed elements of the Eaststarch joint venture within Discontinued Operations in the financial year ending 31 March 2016. In light of this, in its presentation of adjusted performance measures, the Group will cease the use of proportionate consolidation of joint ventures and adopt equity accounting for joint ventures.

We will publish shortly on our website (www.tateandlyle.com) comparative financial information for the six month period to 30 September 2014 and for the year ended 31 March 2015 showing the impact of these changes.

OUTLOOK

Overall, before the impact of exchange rate movements1 and the final timing of the completion of the Eaststarch transaction, expectations for the Group’s full year performance remain unchanged from our guidance issued at our Full Year results in May 2015.

1 Guidance assumed exchange rate of GBP: USD £1.00:$1.54.

END

A conference call will be held today at 8:00am BST, hosted by Javed Ahmed, Chief Executive and Nick Hampton, Chief Financial Officer. Participants are requested to dial in at least 10 minutes before the commencement of the call. Dial in details are as follows:

Standard International Access: +44 (0) 20 3003 2666

Password: Tate & Lyle

UK replay number: +44 (0) 20 8196 1998

Replay access PIN: 3562780

A replay of this call will be available after the end of the live call for 14 days until 21 October 2015.

For more information contact Tate & Lyle PLC:

Christopher Marsh, VP, Investor and Media Relations

Tel: +44 (0) 20 7257 2110 or Mobile: +44 (0) 7796 192 688

Andrew Lorenz (FTI Consulting), Media Relations

Tel: +44 (0) 203 727 1323 or Mobile: +44 (0) 7775 641 807

About Tate & Lyle:

Tate & Lyle is a global provider of ingredients and solutions to the food, beverage and other industries, with operations in over 30 locations worldwide.

Tate & Lyle operates through two global divisions, Speciality Food Ingredients and Bulk Ingredients, supported by our Innovation and Commercial Development and Global Operations groups. The Group's strategy is to become a leading global provider of Speciality Food Ingredients through a disciplined focus on growth, and by driving Bulk Ingredients for sustained cash generation to fuel this growth.

Speciality Food Ingredients consists of three platforms: Texturants, which includes speciality starches and stabilisers; Sweeteners, which comprises nutritive sweeteners and our range of no-calorie sweeteners including SPLENDA® Sucralose; and our Health and Wellness portfolio which includes speciality fibres and our salt-reduction offering. Additionally, our Food Systems business provides a wide variety of blended ingredient solutions.

Tate & Lyle Bulk Ingredients includes bulk sweeteners, industrial starches and fermentation products (primarily acidulants). Corn co-products from both divisions are primarily sold as animal feed.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2015, Tate & Lyle sales totalled £2.7 billion. For more information, please visit http://www.tateandlyle.com. SPLENDA® is a trademark of Heartland Consumer Products LLC.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151007006229/en/

Copyright Business Wire 2015

Date   Source Headline
2nd Jul 20245:32 pmRNSTransaction in Own Shares
2nd Jul 202411:30 amRNSHolding(s) in Company
1st Jul 20245:29 pmRNSTransaction in Own Shares
1st Jul 202412:30 pmRNSTotal Voting Rights
28th Jun 20245:59 pmRNSTransaction in Own Shares
27th Jun 20245:37 pmRNSTransaction in Own Shares
27th Jun 20244:30 pmRNSCompletes sale of remaining interest in Primient
27th Jun 20243:30 pmRNSHolding(s) in Company
26th Jun 20245:38 pmRNSTransaction in Own Shares
25th Jun 20245:50 pmRNSTransaction in Own Shares
24th Jun 20245:35 pmRNSTransaction in Own Shares
24th Jun 20243:30 pmRNSHolding(s) in Company
21st Jun 20245:45 pmRNSTransaction in Own Shares
21st Jun 20242:45 pmRNSUpdate to the Notice of AGM 2024
20th Jun 20246:03 pmRNSTransaction in Own Shares
20th Jun 20247:05 amRNSLaunch of Share Buyback
20th Jun 20247:00 amRNSCombination of Tate & Lyle and CP Kelco
4th Jun 20245:22 pmRNSAnnual Financial Report and Notice of AGM
4th Jun 202411:00 amRNSDirector/PDMR Shareholding
3rd Jun 202412:00 pmRNSTotal Voting Rights
30th May 202412:15 pmRNSHolding(s) in Company
23rd May 20247:00 amRNSFinal Results
23rd May 20247:00 amRNSSale of remaining interest in Primient JV to KPS
20th May 20241:00 pmRNSDirectorate Change
17th May 20243:30 pmRNSHolding(s) in Company
14th May 20243:30 pmRNSHolding(s) in Company
13th May 202410:00 amRNSHolding(s) in Company
8th May 20243:15 pmRNSHolding(s) in Company
1st May 20242:30 pmRNSTotal Voting Rights
25th Apr 20243:45 pmRNSHolding(s) in Company
24th Apr 20247:00 amRNSDirectorate Change
22nd Apr 20242:30 pmRNSDirector/PDMR Shareholding
19th Apr 202410:15 amRNSHolding(s) in Company
17th Apr 20244:15 pmRNSHolding(s) in Company
17th Apr 202410:30 amRNSHolding(s) in Company
15th Apr 202410:30 amRNSHolding(s) in Company
10th Apr 20243:45 pmRNSHolding(s) in Company
8th Apr 202411:15 amRNSHolding(s) in Company
5th Apr 20243:45 pmRNSHolding(s) in Company
4th Apr 20244:15 pmRNSHolding(s) in Company
4th Apr 202412:30 pmRNSHolding(s) in Company
4th Apr 202411:30 amRNSDirector/PDMR Shareholding
2nd Apr 202412:45 pmRNSTotal Voting Rights
2nd Apr 202411:30 amRNSHolding(s) in Company
28th Mar 202411:45 amRNSHolding(s) in Company
25th Mar 202411:45 amRNSHolding(s) in Company
21st Mar 20244:10 pmRNSHolding(s) in Company
20th Mar 20243:00 pmRNSHolding(s) in Company
20th Mar 202412:00 pmRNSHolding(s) in Company
19th Mar 20242:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.